Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use caco-2 as a surrogate for human intestinal permeability measurements

AAPS Journal

Volumn 15, Issue 2, 2013, Pages 483-497

  Larregieu, Caroline A ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biopharmaceutics Classification System (BCS); biowaiver; Caco 2 cells; Food and Drug Administration (FDA); human intestinal permeability; in silico modeling; in vitro screening

Indexed keywords

AMOXICILLIN; BREAST CANCER RESISTANCE PROTEIN; CEFADROXIL; CEFALEXIN; CEFRADINE; CEFTIBUTEN; ENALAPRIL; GABAPENTIN; LAMIVUDINE; LEVODOPA; LISINOPRIL; LORACARBEF; MULTIDRUG RESISTANCE PROTEIN 2; NUCLEOSIDE TRANSPORTER; OFLOXACIN; PEPTIDE TRANSPORTER 1; PREGABALIN; ZIDOVUDINE;

ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; COMPUTER MODEL; CONTROLLED STUDY; DISEASE MARKER; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG PENETRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHILICITY; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; MEMBRANE PERMEABILITY; NONHUMAN; PRACTICE GUIDELINE; PREDICTION; PROTEIN EXPRESSION; RAT;

CACO-2 CELLS; COMPUTER SIMULATION; DRUG APPROVAL; DRUG DISCOVERY; GUIDELINES AS TOPIC; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

EID: 84877045938     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9456-8     Document Type: Article

References (143)

1. Testa B, Caldwell J. Prodrugs revisited: The "ad hoc" approach as a complement to ligand design. Med Res Rev. 1996;16(3):233-41.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
3. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. US FDA website 2000: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070246.pdf.
4. Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37(10-11):1015-51.
5. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46(1-3):27-43.
6. Ungell A-L, Karlsson J. Cell cultures in drug discovery: An industrial perspective. In: Van de Waterbeemd H, Lennernäs H, Artursson P, editors. Drug bioavailability: Estimation of solubility, permeability, absorption and bioavailability. Weinheim: Wiley; 2004.
7. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989;96(3):736-49.
8. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175(3):880-5.
9. Lennernas H, Palm K, Fagerholm U, Artursson P. Comparison between active and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human jejunum in vivo. Int J Pharm. 1996;127(1):103-7.
10. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm Res. 1997;14(6):763-6.
11. Benet LZ, Larregieu CA. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin Pharmacol Ther. 2010;88(3):405-7.
12. Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, Yu LX. Biopharmaceutics classification of selected beta-blockers: Solubility and permeability class membership. Mol Pharmaceutics. 2007;4(4):608-14.
13. Ungell AL. Caco-2 replace or refine? Drug Discov Today Tech. 2004;1(4):423-30.
14. Sun H, Chow EC, Liu S, Du Y, Pang KS. The Caco-2 cell monolayer: Usefulness and limitations. Expert Opin Drug Metabol Toxicol. 2008;4(4):395-411.
15. Press B, Di Grandi D. Permeability for intestinal absorption: Caco-2 assay and related issues. Curr Drug Metab. 2008;9(9):893-900.
16. Cheng KC, Li C, Uss AS. Prediction of oral drug absorption in humans - from cultured cell lines and experimental animals. Expert Opin Drug Metabol Toxicol. 2008;4(5):581-90.
17. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov. 2010;9(8):597-614.
18. Chen ML, Amidon GL, Benet LZ, Lennernas H, Yu LX. The BCS, BDDCS, and regulatory guidances. Pharm Res. 2011;28(7):1774-8.
19. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res. 2002;19(10):1400-16.
20. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabol Dispos. 2007;35(8):1333-40.
21. Chu XY, Sanchez-Castano GP, Higaki K, Oh DM, Hsu CP, Amidon GL. Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther. 2001;299(2):575-82.
22. Behrens I, Kamm W, Dantzig AH, Kissel T. Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. J Pharm Sci. 2004;93(7):1743-54.
23. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci. 2008;35(5):383-96.
24. Chong S, Dando SA, Soucek KM, Morrison RA. In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res. 1996;13(1):120-3.
25. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, et al. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci. 2006;29(3-4):269-77.
26. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: Comparison between human segments and Caco-2 cells. Eur J Pharm Sci. 2006;28(4):291-9.
27. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition. Xenobiotica. 2006;36(10-11):963-88.
28. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metabol Pharmacokinet. 2005;20(6):452-77.
29. Alsenz J, Haenel E. Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. Pharm Res. 2003;20(12):1961-9.
30. Gres MC, Julian B, Bourrie M, Meunier V, Roques C, Berger M, et al. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line. Pharm Res. 1998;15(5):726-33.
31. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci. 1999;88(1):28-33.
32. Jung SJ, Choi SO, Um SY, Kim JI, Choo HY, Choi SY, et al. Prediction of the permeability of drugs through study on quantitative structure-permeability relationship. J Pharm Biomed Anal. 2006;41(2):469-75.
33. Lennernas H. Human intestinal permeability. J Pharm Sci. 1998;87(4):403-10.
34. Li C, Liu T, Cui X, Uss AS, Cheng KC. Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J Biomol Screen. 2007;12(8):1084-91.
35. Markowska M, Oberle R, Juzwin S, Hsu CP, Gryszkiewicz M, Streeter AJ. Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J Pharmacol Toxicol Meth. 2001;46(1):51-5.
36. Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res. 1998;15(9):1490-4.
37. Balimane PV, Chong S, Patel K, Quan Y, Timoszyk J, Han YH, et al. Peptide transporter substrate identification during permeability screening in drug discovery: Comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007;30(4):507-18.
38. Tsuji A. Transporter-mediated drug interactions. Drug Metabol Pharmacokinet. 2002;17(4):253-74.
39. Li M, Anderson GD, Phillips BR, Kong W, Shen DD, Wang J. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metabol Dispos. 2006;34(4):547-55.
40. Knutter I, Kottra G, Fischer W, Daniel H, Brandsch M. High-affinity interaction of sartans with H+/peptide transporters. Drug Metabol Dispos. 2009;37(1):143-9.
41. Chen ML, Yu L. The use of drug metabolism for prediction of intestinal permeability. Mol Pharmaceutics. 2009;6(1):74-81.
42. Terada T, Saito H, Mukai M, Inui K. Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: Localization of PEPT1 and transport of beta-lactam antibiotics. J Pharmacol Exp Ther. 1997;281(3):1415-21.
43. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci. 2000;10(3):195-204.
44. Watanabe K, Jinriki T, Sato J. Effects of progesterone and norethisterone on cephalexin uptake in the human intestinal cell line Caco-2. Biol Pharm Bull. 2004;27(4):559-63.
45. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, et al. CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999;88(3):347-50.
46. Friedman DI, Amidon GL. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: Enalapril and fosinopril. Pharm Res. 1989;6(12):1043-7.
47. Fossati L, Dechaume R, Hardillier E, Chevillon D, Prevost C, Bolze S, et al. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs. Int J Pharm. 2008;360(1-2):148-55.
48. Dantzig AH, Duckworth DC, Tabas LB. Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. Biochim Biophys Acta. 1994;1191(1):7-13.
49. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61(4):729-37.
50. Su TZ, Feng MR, Weber ML. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005;313(3):1406-15.
51. Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R. Absorption of ofloxacin isomers in the rat small intestine. Antimicrob Agents Chemother. 1997;41(10):2274-7.
52. Mensch J, Melis A, Mackie C, Verreck G, Brewster ME, Augustijns P. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. Eur J Pharm Biopharm. 2010;74(3):495-502.
53. Jezyk N, Li C, Stewart BH, Wu X, Bockbrader HN, Fleisher D. Transport of pregabalin in rat intestine and Caco-2 monolayers. Pharm Res. 1999;16(4):519-26.
54. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch. 2004;447(5):728-34.
55. de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci. 2009;98(11):4413-9.
56. Mueller BU, Lewis LL, Yuen GJ, Farley M, Keller A, Church JA, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 1998;42(12):3187-92.
57. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-47.
58. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci. 1998;6(4):317-24.
59. Yamashita S, Tanaka Y, Endoh Y, Taki Y, Sakane T, Nadai T, et al. Analysis of drug permeation across Caco-2 monolayer: Implication for predicting in vivo drug absorption. Pharm Res. 1997;14(4):486-91.
60. Linnankoski J, Makela J, Palmgren J, Mauriala T, Vedin C, Ungell AL, et al. Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models. J Pharm Sci. 2010;99(4):2166-75.
61. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci. 2000;89(1):63-75.
62. Tam KY, Avdeef A, Tsinman O, Sun N. The permeation of amphoteric drugs through artificial membrane - an in combo absorption model based on paracellular and transmembrane permeability. J Med Chem. 2010;53(1):392-401.
63. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002;300(3):918-24.
64. Tavelin S, Taipalensuu J, Soderberg L, Morrison R, Chong S, Artursson P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm Res. 2003;20(3):397-405.
65. Adson A, Burton P, Raub T, Barsuhn C, Audus K, Ho N. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: Uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci. 1995;84(10):1197-204.
66. Neuhoff S, Ungell AL, Zamora I, Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug-drug interactions. Pharm Res. 2003;20(8):1141-8.
67. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, et al. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005;315(1):337-45.
68. Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: The role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharmaceutics. 2009;6(1):19-28.
69. Pade V, Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res. 1997;14(9):1210-5.
70. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther. 1999;288(1):171-8.
71. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, et al. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004;308(3):1021-9.
72. Chiou WL, Chung SM, Wu TC, Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther. 2001;39(3):93-101.
73. Bourdet DL, Pollack GM, Thakker DR. Intestinal absorptive transport of the hydrophilic cation ranitidine: A kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm Res. 2006;23(6):1178-87.
74. Alt A, Potthast H, Moessinger J, Sickmuller B, Oeser H. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products. Eur J Pharm Biopharm. 2004;58(1):145-50.
75. Nellans N. Paracellular intestinal transport: modulation of absorption. Adv Drug Deliv Rev. 1991;7:339-64.
76. Pappenheimer JR, Reiss KZ. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J Membr Biol. 1987;100(2):123-36.
77. Madara JL. Regulation of the movement of solutes across tight junctions. Annu Rev Physiol. 1998;60:143-59.
78. Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci. 2008;97(2):712-25.
79. Caldwell GW, Easlick SM, Gunnet J, Masucci JA, Demarest K. In vitro permeability of eight beta-blockers through Caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. J Mass Spectrom. 1998;33(7):607-14.
80. Avdeef A, Tam KY. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? J Med Chem. 2010;53(9):3566-84.
81. Avdeef A, Artursson P, Neuhoff S, Lazorova L, Grasjo J, Tavelin S. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. Eur J Pharm Sci. 2005;24(4):333-49.
82. Akamatsu M, Fujikawa M, Nakao K, Shimizu R. In silico prediction of human oral absorption based on QSAR analyses of PAMPA permeability. Chem Biodivers. 2009;6(11):1845-66.
83. Bergstrom CA, Strafford M, Lazorova L, Avdeef A, Luthman K, Artursson P. Absorption classification of oral drugs based on molecular surface properties. J Med Chem. 2003;46(4):558-70.
84. Castillo-Garit JA, Marrero-Ponce Y, Torrens F, Garcia-Domenech R. Estimation of ADME properties in drug discovery: predicting Caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices. J Pharm Sci. 2008;97(5):1946-76.
85. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G. Predicting P-glycoprotein effects on oral absorption: Correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004;21(5):819-26.
86. Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci. 2006;27(4):354-62.
87. Cruciani G, Pastor M, Guba W. VolSurf: A new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci. 2000;11 Suppl 2:S29-39.
88. Di Fenza A, Alagona G, Ghio C, Leonardi R, Giolitti A, Madami A. Caco-2 cell permeability modelling: A neural network coupled genetic algorithm approach. J Comput Aided Mol Des. 2007;21(4):207-21.
89. Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, et al. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem. 2009;17(19):6983-92.
90. Ekins S, Durst GL, Stratford RE, Thorner DA, Lewis R, Loncharich RJ, et al. Three-dimensional quantitative structure-permeability relationship analysis for a series of inhibitors of rhinovirus replication. J Chem Inf Comput Sci. 2001;41(6):1578-86.
91. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43(20):3714-7.
92. Foger F, Kopf A, Loretz B, Albrecht K, Bernkop-Schnurch A. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs. Amino Acids. 2008;35(1):233-41.
93. Fujiwara S, Yamashita F, Hashida M. Prediction of Caco-2 cell permeability using a combination of MO-calculation and neural network. Int J Pharm. 2002;237(1-2):95-105.
94. Goodwin JT, Mao B, Vidmar TJ, Conradi RA, Burton PS. Strategies toward predicting peptide cellular permeability from computed molecular descriptors. J Pept Res. 1999;53(4):355-69.
95. Grice JE, Cross SE, Brownlie C, Roberts MS. The application of molecular structural predictors of intestinal absorption to screening of compounds for transdermal penetration. J Pharm Pharmacol. 2010;62(6):750-5.
96. Guangli M, Yiyu C. Predicting Caco-2 permeability using support vector machine and chemistry development kit. J Pharm Pharm Sci. 2006;9(2):210-21.
97. Hilgers AR, Smith DP, Biermacher JJ, Day JS, Jensen JL, Sims SM, et al. Predicting oral absorption of drugs: A case study with a novel class of antimicrobial agents. Pharm Res. 2003;20(8):1149-55.
98. Hou TJ, Zhang W, Xia K, Qiao XB, Xu XJ. ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. J Chem Inf Comput Sci. 2004;44(5):1585-600.
99. Krarup LH, Christensen IT, Hovgaard L, Frokjaer S. Predicting drug absorption from molecular surface properties based on molecular dynamics simulations. Pharm Res. 1998;15(7):972-8.
100. Kulkarni A, Han Y, Hopfinger AJ. Predicting Caco-2 cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis. J Chem Inf Comput Sci. 2002;42(2):331-42.
101. Liang E, Chessic K, Yazdanian M. Evaluation of an accelerated Caco-2 cell permeability model. J Pharm Sci. 2000;89(3):336-45.
102. Linnankoski J, Ranta VP, Yliperttula M, Urtti A. Passive oral drug absorption can be predicted more reliably by experimental than computational models - fact or myth. Eur J Pharm Sci. 2008;34(2-3):129-39.
103. Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP. Prediction of drug transport through the blood-brain barrier in vivo: A comparison between two in vitro cell models. Pharm Res. 2002;19(7):976-81.
104. Marrero Ponce Y, Cabrera MA, Romero V, Ofori E, Montero LA. Total and local quadratic indices of the "Molecular Pseudograph's Atom Adjacency Matrix". Application to prediction of Caco-2 permeability of drugs. Int J Mol Sci. 2003;4:512-36.
105. Marrero Ponce Y, Cabrera Pérez MA, Romero Zaldivar V, Gonzalez Diaz H, Torrens F. A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci. 2004;7(2):186-99.
106. Marrero Ponce Y, Cabrera Pérez MA, Romero Zaldivar V, Bermejo Sanz M, Siverio Mota D, Torrens F. Prediction of intestinal epithelial transport of drug in (Caco-2) cell culture from molecular structure using in silico approaches during early drug discovery. Internet Electron J Mol Des. 2005;4:124-50.
107. Matsson P, Bergstrom CA, Nagahara N, Tavelin S, Norinder U, Artursson P. Exploring the role of different drug transport routes in permeability screening. J Med Chem. 2005;48(2):604-13.
108. Nordqvist A, Nilsson J, Lindmark T, Eriksson A, Garberg P, Kihlen M. A general model for prediction of Caco-2 cell permeability. QSAR Comb Sci. 2004;23(5):303-10.
109. Norinder U, Osterberg T, Artursson P. Theoretical calculation and prediction of Caco-2 cell permeability using MolSurf parametrization and PLS statistics. Pharm Res. 1997;14(12):1786-91.
110. Norinder U, Osterberg T. Theoretical calculation and prediction of drug transport processes using simple parameters and partial least squares projections to latent structures (PLS) statistics. The use of electrotopological state indices. J Pharm Sci. 2001;90(8):1076-85.
111. Osterberg T, Norinder U. Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics. J Chem Inf Comput Sci. 2000;40(6):1408-11.
112. Osterberg T, Norinder U. Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/logP and ACD/ChemSketch descriptors. Eur J Pharm Sci. 2001;12(3):327-37.
113. Paixao P, Gouveia LF, Morais JA. Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks. Eur J Pharm Sci. 2010;41(1):107-17.
114. Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P. Correlation of drug absorption with molecular surface properties. J Pharm Sci. 1996;85(1):32-9.
115. Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors. J Med Chem. 1998;41(27):5382-92.
116. Parrott N, Lave T. Prediction of intestinal absorption: Comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci. 2002;17(1-2):51-61.
117. Pickett SD, McLay IM, Clark DE. Enhancing the hit-to-lead properties of lead optimization libraries. J Chem Inf Comput Sci. 2000;40(2):263-72.
118. Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS. In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem. 2005;48(3):805-11.
119. Ren S, Lien EJ. Caco-2 cell permeability vs human gastrointestinal absorption: QSPR analysis. Prog Drug Res. 2000;54:1-23.
120. Skolnik S, Lin X, Wang J, Chen XH, He T, Zhang B. Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J Pharm Sci. 2010;99(7):3246-65.
121. Stenberg P, Norinder U, Luthman K, Artursson P. Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem. 2001;44(12):1927-37.
122. Thomas S, Brightman F, Gill H, Lee S, Pufong B. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. J Pharm Sci. 2008;97(10):4557-74.
123. Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, Bengtsson UH. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: Structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci. 2003;92(6):1216-33.
124. van de Waterbeemd H, Camenisch G, Folkers G, Raevsky OA. Estimation of Caco-2 cell permeability using calculated molecular descriptors. Quant Struct-Act Relat. 1996;15(6):480-90.
125. Yamashita F, Wanchana S, Hashida M. Quantitative structure/property relationship analysis of Caco-2 permeability using a genetic algorithm-based partial least squares method. J Pharm Sci. 2002;91(10):2230-9.
126. Zhang X, Shedden K, Rosania GR. A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Mol Pharmaceutics. 2006;3(6):704-16.
127. Zhu C, Jiang L, Chen TM, Hwang KK. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem. 2002;37(5):399-407.
128. Saitoh R, Sugano K, Takata N, Tachibana T, Higashida A, Nabuchi Y, et al. Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm Res. 2004;21(5):749-55.
129. Benet LZ. The role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System) in drug development. J Pharm Sci. 2012: (Epub Ahead of Print).
130. Kotze AF, Thanou MM, Luebetaen HL, de Boer AG, Verhoef JC, Junginger HE. Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: In vitro evaluation in intestinal epithelial cells (Caco-2). J Pharm Sci. 1999;88(2):253-7.
131. Zheng K, Trivedi M, Siahaan TJ. Structure and function of the intercellular junctions: Barrier of paracellular drug delivery. Curr Pharm Des. 2006;12(22):2813-24.
132. Umapathy NS, Ganapathy V, Ganapathy ME. Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004;21(7):1303-10.
133. Hatanaka T, Haramura M, Fei YJ, Miyauchi S, Bridges CC, Ganapathy PS, et al. Transport of amino acid-based prodrugs by the Na(+)- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004;308(3):1138-47.
134. Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci. 2008;97(3):1109-34.
135. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998;15(8):1154-9.
136. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci. 2000;2(1):E6.
137. Collett A, Sims E, Walker D, He YL, Ayrton J, Rowland M, et al. Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res. 1996;13(2):216-21.
138. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharmaceutics. 2004;1(1):85-96.
139. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res. 1996;13(9):1336-42.
140. Simon Z, Katja B, Robert R, Bor K, Albin K. Do the recommended standards for in vitro biopharmaceutic classification of drug permeability meet the "passive transport" criterion for biowaivers? Curr Drug Metab. 2012:(Epub Ahead of Print).
141. Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: An exception or the rule? Nat Rev Drug Discov. 2008;7(3):205-20.
142. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
143. US Department of Health and Human Services, Food and Drug Administration, Critical Path Initiative Challenges and Opportunities Report. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. US FDA website. 2004: http://www.fda.gov/ScienceResearch/ SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262. htm.